Evidence map›Paper›PMID 35763545›Full record

ArticlePLoS pathogens2022

A Hepatitis C virus genotype 1b post-transplant isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo.

Christian Heuss, Paul Rothhaar, Rani Burm, Ji-Young Lee, Philipp Ralfs, Uta Haselmann, Luisa J Ströh, Ombretta Colasanti, Cong Si Tran, Noemi Schäfer and 9 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 3 countries.

Christian HeussDepartment of Infectious Diseases, Molecular Virology, Section virus-host interactions, Heidelberg University, Heidelberg, Germany.
Paul RothhaarDepartment of Infectious Diseases, Molecular Virology, Section virus-host interactions, Heidelberg University, Heidelberg, Germany.
Rani BurmLaboratory of Liver Infectious Diseases, Ghent University, Gent, Belgium.
Ji-Young LeeDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.
Philipp RalfsDepartment of Infectious Diseases, Molecular Virology, Section virus-host interactions, Heidelberg University, Heidelberg, Germany.
Uta HaselmannDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.
Luisa J StröhInstitute of Virology, Hannover Medical School, Hannover, Germany.
Ombretta ColasantiDepartment of Infectious Diseases, Molecular Virology, Section virus-host interactions, Heidelberg University, Heidelberg, Germany.
Cong Si TranDepartment of Infectious Diseases, Molecular Virology, Section virus-host interactions, Heidelberg University, Heidelberg, Germany.
Noemi SchäferDepartment of Infectious Diseases, Molecular Virology, Section virus-host interactions, Heidelberg University, Heidelberg, Germany.
Paul SchnitzlerDepartment of Infectious Diseases Virology, University Hospital Heidelberg, Heidelberg, Germany.
Uta MerleDepartment of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany.
Ralf BartenschlagerDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany.
Arvind H PatelMRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Frederik GrawBioQuant - Center for Quantitative Biology, Heidelberg University, Heidelberg, Germany.
Thomas KreyInstitute of Virology, Hannover Medical School, Hannover, Germany.
Vibor LaketaDepartment of Infectious Diseases Virology, University Hospital Heidelberg, Heidelberg, Germany.
Philip MeulemanLaboratory of Liver Infectious Diseases, Ghent University, Gent, Belgium.
Volker LohmannDepartment of Infectious Diseases, Molecular Virology, Section virus-host interactions, Heidelberg University, Heidelberg, Germany.ORCID 0000-0001-8719-7608
Heidelberg University · DEGhent University · BEMedizinische Hochschule Hannover · DEGerman Cancer Research Center · DEMRC University of Glasgow Centre for Virus Research · GB

Funding

Medical Research Council MC_UU_12014/1Medical Research Council MC_UU_12014/2Medical Research Council MC_UU12014/2
6 · The paper itself

Abstract

Hepatitis C virus (HCV) is highly diverse and grouped into eight genotypes (gts). Infectious cell culture models are limited to a few subtypes and isolates, hampering the development of prophylactic vaccines. A consensus gt1b genome (termed GLT1) was generated from an HCV infected liver-transplanted patient. GLT1 replicated to an outstanding efficiency in Huh7 cells upon SEC14L2 expression, by use of replication enhancing mutations or with a previously developed inhibitor-based regimen. RNA replication levels almost reached JFH-1, but full-length genomes failed to produce detectable amounts of infectious virus. Long-term passaging led to the adaptation of a genome carrying 21 mutations and concomitant production of high levels of transmissible infectivity (GLT1cc). During the adaptation, GLT1 spread in the culture even in absence of detectable amounts of free virus, likely due to cell-to-cell transmission, which appeared to substantially contribute to spreading of other isolates as well. Mechanistically, genome replication and particle production efficiency were enhanced by adaptation, while cell entry competence of HCV pseudoparticles was not affected. Furthermore, GLT1cc retained the ability to replicate in human liver chimeric mice, which was critically dependent on a mutation in domain 3 of nonstructural protein NS5A. Over the course of infection, only one mutation in the surface glycoprotein E2 consistently reverted to wildtype, facilitating assembly in cell culture but potentially affecting CD81 interaction in vivo. Overall, GLT1cc is an efficient gt1b infectious cell culture model, paving the road to a rationale-based establishment of new infectious HCV isolates and represents an important novel tool for the development of prophylactic HCV vaccines.

Indexed as

HepacivirusHepatitis CAnimalsCell Culture TechniquesGenotypeHumansMiceMutationViral Nonstructural ProteinsVirus ReplicationViral Nonstructural Proteins

Identifiers

PMID35763545
PMCPMC9273080
OpenAlexW4283689900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.